

IQECAD INFORMATION MEETING

"Last results from IQECAD (data from 2021)",

Mme Suchsia Chao, from Sciensano.

SWEET Benchmarking - just a nice to have? The Luxembourg experience."
Dr. Michael Witsch, from Centre Hospitalier de Luxembourg.

"First results of the real-world impact and safety of initiation of the Medtronic MiniMedTM 780G in children with type 1 diabetes aged 2-6 years"

Mme. Jolien De Meulemeester, from UZ Leuven.

11/01/2024 Park Inn by Radisson Brussels Airport Suchsia Chao, Sciensano

> Rue Juliette Wytsmanstraat 14 | 1050 Brussels | Belgium T +32 2 642 51 11 | F +32 2 642 54 10 | email: info@sciensano.be | https://www.sciensano.be



healthy all life long

IQECAD MEETING

"Last results from IQECAD (data from 2021)", Mme Suchsia Chao, from Sciensano.


11/01/2024 Park Inn by Radisson Brussels Airport Suchsia Chao, Sciensano

> Rue Juliette Wytsmanstraat 14 | 1050 Brussels | Belgium T +32 2 642 51 11 | F +32 2 642 54 10 | email: info@sciensano.be | https://www.sciensano.be




Epidemiology

Evolution of the prevalence and incidence DT1 (based on IQECAD data)





Audit 2021




2021 Data Collection


- 16 pediatric diabetology centers
- 3619 patients with T1D & < 19 years were recorded

- 95.5 % of eligible patients were included




Characteristics of the population (2008-2021)





Developpement








Z-score weight median: 0.40





Z-score BMI median : 0.56













Audit 2008-2021: Processus indicators

Evolution - Processus indicators




Audit 2008-2021: Process indicators

Evolution - process indicators



Audit 2008-2021: Processus indicators


Evolution - Processus indicators Screening for complications and co-morbidities



- Celiac screening
- Thyroid screening
- retinopaty screening (target pop)
- Retinopaty screening
- Nephropathy screening
- Nephropathy screening (target pop)
- Lipid profile screening
- Lipid profile screening (target pop)
- Neuropathy screening

Audit 2008-2021: Processus indicators


Evolution - Processus indicators Screening for complications and co-morbidities




HbA1c Evolution


- Available in your personalized feedback.
- An improvement in HbA1c was observed in 14 out of 17 centers.
- For 8 centers, this decrease was statistically significant (lines in **bold**)
- For 3 centers:
 HbA1c increased over time <u>BUT</u> had
 the lawest level in 2000
 - the lowest level in 2008.





In which subpopulations the decrease in HbA1c was most pronounced?






Dash lines = girls; solid lines = boy

and gender


Age



Dash lines = girls; solid lines = boy

and gender


Age





Dash lines = girls; solid lines = boy


and gender

Age











Parents' ethnicity



Improvement can be also explained by the fact that patients on pump have less psychosocial distress.


Significant decrease.



Improvement can be also explained by the fact that patients on pump have less psychosocial distress.


* Significant decrease.

Insulin regimen evolution



Since 2008:

- Increase of the use of the insulin pump.
- Decrease of the use of the "<2 inj/day".
- The older the patient, the more intensive the treatment
- → Increase in the use of diabetes
 technologies associated with lower HbA1c.
 Use of a pump system was associated
 with the best HbA1c (adjusted for
 psychosocial-distress)



Comparison with national registries:


• National Paediatric Diabetes Audit of

England and Wales (NPDA)

• Sweden national registry (SWEDIABKIDS)

					Swed	len** (2021)					
	0%	10%	20%	30%	40%	50%	60%	70%	80%	90%	100%
0.6.1///0	SWEDIABKIDS	39.1%			15.8%		24.5%			16.7%	
0-6 yrs	IQECAD	16.2% 11.4%			25.3%		22.	22.5%			10.4%
7 11 1/20	SWEDIABKIDS		15.1%		15.1%		23.3%		17.0%	<mark>2.9%</mark>	
7-11 yrs	IQECAD	22.2%		13.7%		25.5%		19.2%		0.5%	8.9%
	SWEDIABKIDS	31	31.9%		12.7%		19.8%	20.0%		7.8%	7.7%
12-17 yrs	IQECAD	16.8%	6.8% 9.6%		18.6%		23.4% 13		2% 18.4		%
	,	■≤(6.5%	6.6% - 6.8%	6.9	% - 7.3%	7.4 - 8.0%	8.1-8.6 %	, ∎≥	:8.7%	

Source: * https://www.rcpch.ac.uk/sites/default/files/2023-11/npda_2021-22_apendix_1_extended_analysis.pdf



Comparison with national registries:


• National Paediatric Diabetes Audit of

England and Wales (NPDA)

• Sweden national registry (SWEDIABKIDS)


					Swed	len** (2021)				
	0%	10%	20%	30%	40%	50%	60%	70%	80%	90%	100%
0.0.1	SWEDIABKIDS	39.1%		15.8%			24.5%		16.7%	2.9%	
0-6 yrs	IQECAD	16.2%	16.2% 11.4%		25.3%		2	22.5%			10.4%
7 11 1/20	SWEDIABKIDS	39.8%				15.1%		23.3%		17.0%	2.9%
7-11 yrs	IQECAD	22.2%	22.2% 13.7%		25.5%			19.2%		0.5%	8.9%
	SWEDIABKIDS	31	.9%				19.8%	20.0%	6	7.8%	7.7%
12-17 yrs	IQECAD	16.8%	9.6%		18.6%		23.4%	13.2	%	18.4	%
		■ ≤6	6.5%	6.6% - 6.8%	6.9	% - 7.3%	7.4 - 8.0%	6 8 .1-8.6%	⁄₀ ■≥	8.7%	

Source: * https://www.rcpch.ac.uk/sites/default/files/2023-11/npda_2021-22_apendix_1_extended_analysis.pdf



					Swee	den** (202	1)				
	0%	10%	20%	30%	40%	50%	60%	70%	80%	90%	1009
	SWEDIABKIDS	39.1%			15.8%			24.5%		16.7%	2.9%
0-6 yrs	IQECAD	16.2% 11.4%		25.3%			22.5%		14.2%		
	SWEDIABKIDS	39.8%				15.1%		23.3%		17.0%	2.9%
7-11 yrs	IQECAD	22.2% 13.7%		13.7%	% 25.5%			19.2%		10.5%	8.9%
	SWEDIABKIDS	3	31.9%		12.7% 1		19.8%	19.8% 20.0%		7.8%	7.7%
12-17 yrs	IQECAD	16.8%	9.6%		18.6%		23.4%	13.	2%	18.4	%
	,	■≤	6.5%	6.6% - 6.8%	6.9	9% - 7.3%	7 .4 - 8.	0% 8.1-8.6	5%	≥8.7%	

Source: * https://www.rcpch.ac.uk/sites/default/files/2023-11/npda_2021-22_apendix_1_extended_analysis.pdf



					Swede	en** (2021)					
	0%	10%	20%	30%	40%	50%	60%	70%	80%	90%	1009
0.6.1///0	SWEDIABKIDS	39.1%			15.8%			24.5%		16.7%	
0-6 yrs	IQECAD	16.2% 11.4%			25.3%		2	22.5%			10.4%
7-11 yrs	SWEDIABKIDS		39.8%			15.1%		23.3%		17.0%	2.9%
7-11 yis	IQECAD	22.2%	22.2% 13.		3.7% 25.5%			19.2%		0.5%	8.9%
	SWEDIABKIDS	31	31.9%		12.7%	19.8%		20.0%	6	7.8%	7.7%
12-17 yrs	IQECAD	16.8%	9.6%		18.6%		23.4%	13.2	%	18.4	%
		∎≤6	õ.5% ■	6.6% - 6.8%	6.9%	% - 7.3%	7 .4 - 8.0%	8.1-8.6%	% ■≥	8.7%	

Source: * https://www.rcpch.ac.uk/sites/default/files/2023-11/npda_2021-22_apendix_1_extended_analysis.pdf



DIABETES UN

RESEARCH: EPIDEMIOLOGY

International comparison of glycaemic control in people with type 1 diabetes: an update and extension

Regina Prigge, John A. McKnight, Sarah H. Wild 🔀, Aveni Haynes, Timothy W. Jones, Elizabeth A. Davis, Birgit Rami-Merhar, Maria Fritsch, Christine Prchla, Astrid Lavens, Kris Doggen ... See all authors 🗸

First published: 10 December 2021 | https://doi.org/10.1111/dme.14766 | Citations: 13

J. A. McKnight and S. H. Wild are joint senior authors.

Read the full text >

🎘 PDF 🔧 TOOLS < SHARE

Abstract

Aims

To update and extend a previous cross-sectional international comparison of glycaemic control in people with type 1 diabetes.

Prigge R et al International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabet Med. 2022 May;39(5):e14766. doi: 10.1111/dme.14766. Epub 2021 Dec 26. PMID: 34890078.

International comparison (Prigge et al):

- 54,158 children aged < 15 years with
 type 1 diabetes
- 19 countries or regions between 2016 and 2020
- Median HbA1c (IQR) is presented in order of increasing HbA1c.
- ➔ Belgium have a excellent position in the ranking !

Country/Region	Data source	Ν	Median HbA1c % (IQR)	Missing HbA1c (%)
Italy	regional	192	7.2 (6.8; 8.1)	0
Greece	clinic	26	7.2 (6.8; 7.6)	3.8
Belgium	national	2,242	7.3 (6.7; 7.9)	1
Denmark	national	1,869	7.4 (6.7; 8.0)	15.5
Austria	national	1,444	7.4 (6.8; 8.1)	0.6
Netherlands	clinic	583	7.4 (6.9; 8.1)	2.2
Germany	national	17,463	7.5 (6.8; 8.3)	1.3
Slovenia	national	382	7.5 (7.0; 8.1)	0
Australia	regional	627	7.6 (6.9; 8.2)	3.5
England	national	18,514	7.7 (7.0; 8.3)	6.1
Wales	national	1,045	7.7 (7.0; 8.4)	5.6
Scotland	national	1,960	7.8 (7.3; 8.5)	2.2
Finland	regional	131	7.8 (7.3; 8.4)	2.3
France	regional	40	8.0 (7.5; 8.5)	0
Hong Kong	national	228	8.1 (7.3; 9.0)	8.3
Ukraine	national	6,618	8.3 (7.3; 9.7)	13.3
New Zealand	regional	324	8.3 (7.4; 9.6)	8.8
Ireland	clinic	74	8.4 (7.5; 9.2)	12.2
Latvia	national	396	9.1 (7.8; 10.8)	12.1


Prigge R et al International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabet Med. 2022 May;39(5):e14766. doi: 10.1111/dme.14766. Epub 2021 Dec 26. PMID: 34890078.

International comparison (Prigge et al):

- 54,158 children aged < 15 years with
 type 1 diabetes
- 19 countries or regions between 2016 and 2020
- Median HbA1c (IQR) is presented in order of increasing HbA1c.
- ➔ Belgium have a excellent position in the ranking !


Time of coverage & Time in hypoglycemia

New in 2021:Average time of coverage over a period of 14 days ?Average time in hypoglycemia (<70 mg/dl) over a period of 14 days ?</td>




Time in Range (%) (70 to 180 mg/dl)

New in 2021: Average time in range over a period of 14 days (%)?




Time in Range (%) (70 to 180 mg/dl)

New in 2021: Average time in range over a period of 14 days (%)?




Method of blood glucose measurement





Method of blood glucose measurement




Flash Glucose Monitoring is the main method is of blood glucose measurement.

Continuous glucose monitoring
 Fingerstick test
 Flash glucose monitoring



Method of blood glucose measurement



Flash Glucose Monitoring is the main method is of blood glucose measurement.


> Continuous glucose monitoring Fingerstick test Flash glucose monitoring




increase

The finger pricks test


Number of scans per day



Number of scans/day increased when HbA1c decrease



Blood lipids (target population)




84 90 83 76 74 80 70 61.3 61 60 50 40 30 20 10 0 LDL TRIG HDL Target population All patients

* Targets defined by US National Cholesterol Education Program Adult (NCEP ATP III)

- Mean LDL increased with age
- Mean LDL cholesterol significantly higher among girls than boys (92.1 mg/dl vs. 82.8 mg/dl, P<0.0001)
- Mean LDL cholesterol significantly higher among children with no Caucasian parents (89.4 mg/dl vs. 86.3 mg/dl, P<0.05)


Psychosocial distress

Proportion patients with psycho-social distress (N=3640)



35 31.08 30.5 30 17.9 11.8 5 0 6-9 y 10-15 y 16-18 y <6 y (N=245) (N=545) (N=1838) (N=991) Age categories

Psycho-social distress over ages



Conclusion

• The **increase in incidence** of Type 1 diabetes continued. During the COVID-19 : no significant increased of the new cases.

• Continuing **improvement in HbA1c** with increase in the use of diabetes technologies associated with lower HbA1c.

• Significant increase of **overweight children with DT1** (2021: 28% of patients overweighted, and 13% blood pressure in the hypertensive range).

• 1/3 were assessed as having **psychosocial distress** which is related to higher HbA1c.

• Inequalities in HbA1c improvement by age, ethnicity, family structure and insulin regimen. The gap between children of different ethnicities increase over time.

• Annual screening for retinopathy decreased (general and the target population).

• In **international HbA1c comparison**: Belgium proves to have excellent diabetes quality of care






- Presentation on our Sciensano website
- Contact : Suchsia chao

Suchsia.Chao@sciensano.be



Extra: Chronic complications and comorbidities


Evolution of complications and comorbidities 16



sciensano

Extra: Hypoglycemia & DKA

Acute complications



Taken together, in each audit approximately 1 out of 17 patients experienced severe hypoglycaemia in the preceding 3 months. Stable over time Rare event